

## Product Information

# SILu™Prot PTX3, Pentraxin-Related Protein, Human

Recombinant, Expressed in HEK cells, SIL MS Protein Standard, <sup>13</sup>C- and <sup>15</sup>N-Labeled

**MSST0003**

Storage Temperature -20 °C

Synonyms: Tumor necrosis factor alpha-induced protein 5 (TNF alpha-induced protein 5), Tumor necrosis factor-inducible gene 14 protein, (TSG-14)

## Product Description

SILu™Prot PTX3 is a recombinant, stable isotope-labeled human PTX3 which incorporates [<sup>13</sup>C<sub>6</sub>, <sup>15</sup>N<sub>4</sub>]-Arginine and [<sup>13</sup>C<sub>6</sub>, <sup>15</sup>N<sub>2</sub>]-Lysine. Expressed in human 293 cells, it is designed to be used as an internal standard for bioanalysis of PTX3 in mass spectrometry. SILu™Prot PTX3 is a recombinant glycosylated human protein expressed in human 293 cells. It is a homooctamer and a homodecamer consisting of 364 amino acids (monomer) with a calculated molecular mass of 40.4 kDa. It contains no tags.

Pentraxin 3 (PTX3) is a secreted glycosylated protein belonging to the pentraxin superfamily.<sup>1</sup> PTX3 is rapidly produced and released by several cell types, in particular by mononuclear phagocytes, dendritic cells, fibroblasts, and endothelial cells in response to primary inflammatory signals (e.g., toll-like receptor engagement, TNFα, IL-1β).<sup>1</sup> PTX3 behaves as an acute phase response protein, as the blood levels of PTX3, which are low in normal conditions (~25 ng/mL in the mouse, <2 ng/mL in humans), increase rapidly (peaking at 6–8 hours after induction) and dramatically (200–800 ng/mL) during endotoxic shock, sepsis, and other inflammatory and infectious conditions, correlating with the severity of the disease.<sup>2</sup> Under these conditions, PTX3 is a rapid marker for primary local activation of innate immunity and inflammation,<sup>2–6</sup> antiapoptotic cell survival,<sup>2</sup> cell cycle regulation,<sup>3</sup> cell adhesion,<sup>4</sup> tissue remodeling,<sup>5</sup> and lipid transportation.<sup>6</sup> PTX3 gene expression in human endothelial cells is suppressed to a greater extent by pitavastatin than the expression of 6,000 other human genes that have been examined, suggesting PTX3 may be a novel biomarker for inflammatory cardiovascular disease.<sup>7</sup>

Each vial contains ≥10 µg of SILu™Prot PTX3 standard, lyophilized from a solution of phosphate buffered saline. Vial content was determined by the Bradford method using BSA as a calibrator. The correction factor from the Bradford method to amino acid analysis is 110% for this protein.

### Identity

Confirmed by peptide mapping

### Purity

≥95% (SDS-PAGE)

### Heavy amino acid incorporation efficiency

≥98% (MS)

### UniProt

P26022

## Sequence Information

ENSDDYDLMYVNLNDNEIDNGLHPTEDPTPCACGQEHSEWDKLFIMLENSQMRERMLLQATDDVLRGELQRLREELGRLAESLARPC  
APGAPAEARLTSALDELLQATRDAGRRLARMEGAEAQRPEEAGRALAAVLEELRQTRADLHAVQGWAARSWLPAGCETAILFPMRSK  
KIFGSVHPVRPMRLESFSACIWVKATDVLNKTILFSYGTGRNPYEIQLYLSYQSIVFVVGGEENKLVAEAMVSLGRWTHLCGTWNSEE  
GLTSLWVNGELAATTVEMATGHIVPEGGILQIGQEKNGCCVGGGFDETAFSGRLTGFNWDSVLSNEEIRETGGAESCHIRGNIVG  
WGVTEIQPHGGAQYVS

## Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

## Preparation Instructions

Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein in sterile ultrapure water to a final concentration of 100 µg/mL.

## Storage/Stability

Store the lyophilized product at -20 °C. The product is stable for at least 2 years as supplied. After reconstitution, it is recommended to store the protein in working aliquots at -20 °C.

## References

1. Garlanda, C. et al., Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. *Annu Rev Immunol.*, 23, 337-66 (2005).
2. Muller, B. et al., Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. *Crit Care Med.*, 29, 1404-7 (2001).
3. Fazzini, F. et al., PTX3 in small vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. *Arthritis Rheum.*, 44, 2841-50 (2001).
4. Mairuhu A.T. et al., Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. *J Med Virol.*, 4, 547-52 (2005).
5. Azzurri, A. et al., IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. *Microbes Infect.*, 7, 1-8 (2005).
6. Latini, R. et al., Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. *Circulation*, 16, 2349-54 (2004).
7. Inoue, K. et al., Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. *Int. J. Vasc. Med.*, 2012, 657025, 6 pages (2012).

## Legal Information

Sold under license from DuPont, U.S. Patent No. 7,396,688.

This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party.

Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881- 9787 (voice), 1-302-695-1437 (fax), [licensing@dupont.com](mailto:licensing@dupont.com).

---

## Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

## Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://SigmaAldrich.com/techservice).

## Terms and Conditions of Sale

Warranty, use restrictions, and other conditions of sale may be found at [SigmaAldrich.com/terms](https://SigmaAldrich.com/terms).

## Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://SigmaAldrich.com/offices).

The life science business of Merck operates  
as MilliporeSigma in the U.S. and Canada.

Merck, SiLu and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2016-2025 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.  
23222508 Rev 05/25

